|Title:|| Pharmaceutical composition for angiotensin II-mediated diseases|
|Abstract:||This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula ##STR1## wherein R.sup.1 is H or an optionally substituted hydrocarbon residue; R.sup.2 is an optionally esterified carboxyl group; R.sup.3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R.sup.2 ; and Y is a bond, --O--, --S(O)m-- (wherein m is 0, 1 or 2) or --N(R.sup.4)-- (wherein R.sup.4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.|
|Inventor(s):|| Inada; Yoshiyuki (Kawanishi, JP), Kubo; Keiji (Riverside, CA) |
|Assignee:|| Takeda Chemical Industries, Ltd. (Osaka, JP) |
|Filing Date:||Jan 12, 2001|
|Claims:||1. A method for the prophylaxis or treatment of angiotensin II-mediated disease in a mammal in need thereof which comprises administering an effective amount of at least one of |
(.+-.)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7- carboxylate,
2-ethyoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7 -carboxylic acid, or
2-ethoxy-1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methy l]]-1H-benzimidazole-7-carboxylic acid, or a pharmaceutically acceptable salt thereof, in combination with an effective amount of furosemide.
2. A method according to claim 1, wherein the disease is hypertension, cardiac insufficiency, ischemic peripheral circulation disorders, myocardial ischemia, vein insufficiency, progressive cardiac insufficiency after myocardial infarction, diabetic nephritides, nephritis, arteriosclerosis, hyperaldosteronism, dermatosclerosis, glomerulosclerosis, renal insufficiency, central nervous system diseases, sensory disorders, Alzheimer's disease, deficiency of memory, depression, amnesia, senile dementia, anxiety neurosis, catatonia or indisposition, glaucoma, or intraocular high pressure.
3. A method according to claim 1, wherein the disease is hypertension.